Invokana is the brand name for the medication canagliflozin. It belongs to a class of drugs called sodium glucose cotransporter 2 inhibitors which lower blood sugar by acting on the kidneys. The drug blocks the sglt2 protein that normally reabsorbs glucose from the urine back into the bloodstream. By preventing this reabsorption excess glucose is eliminated through urine which reduces circulating blood glucose levels. This mechanism helps patients with type 2 diabetes achieve better glycemic control when used together with diet and exercise. The therapeutic purpose of Invokana is to improve overall glycemic control and may also provide cardiovascular benefits in certain patient populations. The medication is taken orally and works by modulating the kidney's handling of glucose rather than directly stimulating insulin secretion.

Invokana is a medication whose generic name is canagliflozin and it belongs to a class of drugs called sglt2 inhibitors. It is primarily prescribed to improve blood sugar control in adults with type 2 diabetes mellitus. The drug works by blocking the sodium glucose cotransporter two in the kidneys which reduces glucose reabsorption and increases urinary excretion of glucose. This mechanism lowers circulating glucose levels independent of insulin action. By lowering blood glucose Invokana helps reduce the risk of cardiovascular events associated with type 2 diabetes. It also demonstrates modest effectiveness in supporting weight loss and blood pressure reduction as secondary benefits. The therapeutic role of the medication is to complement diet and exercise in managing hyperglycemia. Its pharmacological activity stems from selective inhibition of sglt2 leading to decreased renal glucose reabsorption and increased urinary glucose loss.

Invokana commonly causes urinary tract infections, genital yeast infections, and low blood sugar when used alone, though it is rare. It may lead to dehydration, dizziness, and increased thirst due to fluid loss. Some users experience elevated cholesterol levels and modest weight loss. Rare but notable skin reactions such as rashes can occur. Most side effects are mild and often decrease over time. These effects are generally reversible when the medication is stopped.

Invokana may increase the frequency of urination as it helps the kidneys remove excess glucose. Some people experience urinary tract infections while taking the medication. Elevated blood sugar levels can lead to dehydration if fluid intake is not adequately maintained. A small number of users report low blood pressure especially after the first dose. Genital yeast infections are among the more frequently observed side effects. In rare cases the drug can cause low blood sugar when combined with other antidiabetic agents. Blood tests may occasionally show increased cholesterol levels during treatment. These effects are generally mild and often fade with continued use.